COVID-19 & Cancer

Although vaccination provides a broad immune response against the SARS-CoV-2 virus in most recipients, approved vaccines have shown decreased efficacy in several immunocompromised populations, including patients undergoing treatment for hematologic malignancies. Read More ›

According to data from a European registry, approximately 1 in 6 patients with cancer who recovered from COVID-19 infection experienced long-term sequelae (ie, “long-haul” COVID-19), placing them at increased risk for death or discontinuation of anticancer treatment. Read More ›

Vaccination with the mRNA-1273 vaccine (Moderna) appears safe in patients with solid tumors receiving immunotherapy, chemotherapy, or chemoimmunotherapy. Read More ›

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to receive the free OPM print publications or weekly e‑Newsletter.

I'd like to receive: